We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Assay Detects Norovirus in Fecal Specimens

By LabMedica International staff writers
Posted on 09 Jan 2014
Print article
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
A new real-time reverse transcription polymerase chain reaction (RT-PCR) assay has been evaluated in for the detection of human Norovirus in stool specimens.

Noroviruses are a genetically diverse group of single-stranded ribonucleic acid (RNA), nonenveloped viruses in the Caliciviridae family and are classified into five genogroups by phylogenetic analysis of the capsid protein, of which genogroups II (GII), I (GI), and IV (GIV) are responsible for human outbreak.

Scientists at the Hallym University College of Medicine (Seoul, South Korea) analyzed 281 fecal suspensions (10% to 20% fecal specimen diluted with saline) collected and stored at -70 °C between August 2010 and April 2011. These comprised 109 Norovirus-positive and 172 Norovirus-negative stool samples, as determined using a Norovirus enzyme-linked immunosorbent assay (ELISA).

RNA was extracted from fecal suspensions and prepared using the QIAamp Viral RNA Mini Kit (Qiagen; Hilden, Germany) and the Qiagen QIAcube platform. The AccuPower Norovirus Real-time RT-PCR assay (Bioneer Corporation; Daejeon, South Korea) and the RIDAGENE Norovirus V assay (R-Biopharm, Darmstadt, Germany) were compared as Norovirus assays. Norovirus positivity and genotype were confirmed by direct sequencing.

Of the 109 Norovirus-positive samples by ELISA, 91 (83.5%) were positive by both PCR kits, and two (1.8%) were positive only by the AccuPower kit, whereas 16 cases (14.7%) were negative by both PCR kits. Of the 172 Norovirus-negative samples by ELISA, 159 (92.4%) were negative, and five (2.9%) were positive by both PCR kits, one (0.6%) was positive by the RIDAGENE kit, and seven (4.1%) were positive by the AccuPower kit. The lowest mean numbers of genome copies of GI and GII that could be detected by the AccuPower assay were 12.3 and 5.6 RNA copies/reaction, respectively.

The authors concluded that the AccuPower Norovirus Real-time RT-PCR Kit showed good analytical and clinical performance, including excellent analytical sensitivity and reproducibility, without cross-reactivity and they recommend this assay system as an efficient diagnostic tool for Norovirus infection. Noroviruses are responsible for an estimated 218,000 deaths each year among children younger than five years in developing countries and 1.1 million hospitalizations worldwide. The study was published in the January 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hallym University College of Medicine
Qiagen
Bioneer Corporation 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more